Articles by Ashwin
2 articles
Drug development carries one of the greatest financial risk profiles in the life-science industry. Approximately 90% of drug candidates fail, according to The American Society for Biochemistry and Molecular Biology — a significant share stemming from regulatory hurdles and a resulting lack of clinical efficacy.
In 2020, we wrote about the early but fertile stage of AI development at Johnson and Johnson. Since then, the COVID-19 pandemic and improvements to machine learning have forced important changes in how J&J is using artificial intelligence.
